<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Stem Cell Reports</journal-id>
<journal-id journal-id-type="iso-abbrev">Stem Cell Reports</journal-id>
<journal-title-group>
<journal-title>Stem Cell Reports</journal-title>
</journal-title-group>
<issn pub-type="epub">2213-6711</issn>
<publisher>
<publisher-name>Elsevier</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30392976</article-id>
<article-id pub-id-type="pmc">6235011</article-id>
<article-id pub-id-type="publisher-id">S2213-6711(18)30426-0</article-id>
<article-id pub-id-type="doi">10.1016/j.stemcr.2018.10.003</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Complete Disruption of Autism-Susceptibility Genes by Gene Editing Predominantly Reduces Functional Connectivity of Isogenic Human Neurons</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Deneault</surname>
<given-names>Eric</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>White</surname>
<given-names>Sean H.</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rodrigues</surname>
<given-names>Deivid C.</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ross</surname>
<given-names>P. Joel</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
<xref ref-type="fn" rid="fn1">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Faheem</surname>
<given-names>Muhammad</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zaslavsky</surname>
<given-names>Kirill</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
<xref ref-type="aff" rid="aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Zhuozhi</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alexandrova</surname>
<given-names>Roumiana</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pellecchia</surname>
<given-names>Giovanna</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wei</surname>
<given-names>Wei</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Piekna</surname>
<given-names>Alina</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kaur</surname>
<given-names>Gaganjot</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Howe</surname>
<given-names>Jennifer L.</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kwan</surname>
<given-names>Vickie</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Thiruvahindrapuram</surname>
<given-names>Bhooma</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Walker</surname>
<given-names>Susan</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lionel</surname>
<given-names>Anath C.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pasceri</surname>
<given-names>Peter</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Merico</surname>
<given-names>Daniele</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="fn" rid="fn2">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yuen</surname>
<given-names>Ryan K.C.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Singh</surname>
<given-names>Karun K.</given-names>
</name>
<email>singhk2@mcmaster.ca</email>
<xref ref-type="aff" rid="aff3">3</xref>
<xref ref-type="fn" rid="fn3">9</xref>
<xref ref-type="corresp" rid="cor1">∗</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ellis</surname>
<given-names>James</given-names>
</name>
<email>jellis@sickkids.ca</email>
<xref ref-type="aff" rid="aff4">4</xref>
<xref ref-type="aff" rid="aff5">5</xref>
<xref ref-type="fn" rid="fn3">9</xref>
<xref ref-type="corresp" rid="cor2">∗∗</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Scherer</surname>
<given-names>Stephen W.</given-names>
</name>
<email>stephen.scherer@sickkids.ca</email>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff5">5</xref>
<xref ref-type="aff" rid="aff6">6</xref>
<xref ref-type="fn" rid="fn3">9</xref>
<xref ref-type="corresp" rid="cor3">∗∗∗</xref>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label>Genetics &amp; Genome Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada</aff>
<aff id="aff2"><label>2</label>The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada</aff>
<aff id="aff3"><label>3</label>Stem Cell and Cancer Research Institute, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton L8S 4L8, Canada</aff>
<aff id="aff4"><label>4</label>Developmental &amp; Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada</aff>
<aff id="aff5"><label>5</label>Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 3H7, Canada</aff>
<aff id="aff6"><label>6</label>McLaughlin Centre, University of Toronto, Toronto, ON M5S 3H7, Canada</aff>
<author-notes>
<corresp id="cor1"><label>∗</label>Corresponding author <email>singhk2@mcmaster.ca</email></corresp>
<corresp id="cor2"><label>∗∗</label>Corresponding author <email>jellis@sickkids.ca</email></corresp>
<corresp id="cor3"><label>∗∗∗</label>Corresponding author <email>stephen.scherer@sickkids.ca</email></corresp>
<fn id="fn1">
<label>7</label>
<p id="ntpara0010">Present address: Department of Biology, University of Prince Edward Island, Charlottetown, PE C1A 4P3, Canada</p>
</fn>
<fn id="fn2">
<label>8</label>
<p id="ntpara0015">Present address: Deep Genomics Inc., Toronto, ON M5G 1M1, Canada</p>
</fn>
<fn id="fn3">
<label>9</label>
<p id="ntpara0020">Co-senior author</p>
</fn>
</author-notes>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>11</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
<pub-date pub-type="collection">
<day>13</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>01</day>
<month>11</month>
<year>2018</year>
</pub-date>
<volume>11</volume>
<issue>5</issue>
<fpage>1211</fpage>
<lpage>1225</lpage>
<history>
<date date-type="received">
<day>11</day>
<month>6</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>1</day>
<month>10</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>2</day>
<month>10</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© 2018 The Author(s)</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
</license>
</permissions>
<abstract id="abs0010">
<title>Summary</title>
<p>Autism spectrum disorder (ASD) is phenotypically and genetically heterogeneous. We present a CRISPR gene editing strategy to insert a protein tag and premature termination sites creating an induced pluripotent stem cell (iPSC) knockout resource for functional studies of ten ASD-relevant genes (<italic>AFF2/FMR2, ANOS1, ASTN2, ATRX</italic>, <italic>CACNA1C</italic>, <italic>CHD8, DLGAP2, KCNQ2</italic>, <italic>SCN2A</italic>, <italic>TENM1</italic>). Neurogenin 2 (NGN2)-directed induction of iPSCs allowed production of excitatory neurons, and mutant proteins were not detectable. RNA sequencing revealed convergence of several neuronal networks. Using both patch-clamp and multi-electrode array approaches, the electrophysiological deficits measured were distinct for different mutations. However, they culminated in a consistent reduction in synaptic activity, including reduced spontaneous excitatory postsynaptic current frequencies in <italic>AFF2/FMR2-</italic>, <italic>ASTN2-, ATRX</italic>-, <italic>KCNQ2</italic>-, and <italic>SCN2A</italic>-null neurons. Despite ASD susceptibility genes belonging to different gene ontologies, isogenic stem cell resources can reveal common functional phenotypes, such as reduced functional connectivity.</p>
</abstract>
<abstract abstract-type="author-highlights" id="abs0015">
<title>Highlights</title>
<p>
<list id="ulist0010" list-type="simple">
<list-item id="u0010">
<label>•</label>
<p id="p0010">iPSC knockout resource for functional studies of ten ASD-risk genes</p>
</list-item>
<list-item id="u0015">
<label>•</label>
<p id="p0015">Disruption of common transcriptional networks associated with neurons and synapses</p>
</list-item>
<list-item id="u0020">
<label>•</label>
<p id="p0020">Reduced synaptic activity commonly observed for functionally diverse ASD-risk genes</p>
</list-item>
</list>
</p>
</abstract>
<abstract abstract-type="teaser" id="abs0020">
<p>In this article, Scherer and colleagues present a human induced pluripotent stem cell (iPSC) knockout resource for functional studies of ten genes associated with autism spectrum disorder. They also show that some of these genes, pertaining to diverse functional categories, can underlie common phenotypes in CRISPR-isogenic iPSC-derived glutamatergic neurons.</p>
</abstract>
<kwd-group id="kwrds0010">
<title>Keywords</title>
<kwd>iPSC</kwd>
<kwd>CRISPR</kwd>
<kwd>isogenic</kwd>
<kwd>knockout</kwd>
<kwd>StopTag</kwd>
<kwd>NGN2</kwd>
<kwd>autism</kwd>
<kwd>convergence</kwd>
<kwd>sEPSC</kwd>
</kwd-group>
</article-meta>
<notes>
<p id="misc0010">Published: November 1, 2018</p>
</notes>
</front>
<body>
<sec id="sec1">
<title>Introduction</title>
<p id="p0025">Autism spectrum disorder (ASD) is a lifelong neurodevelopmental condition affecting reciprocal social interaction and communication, accompanied by restricted and repetitive behaviors (<xref ref-type="bibr" rid="bib14">DSM-V, 2013</xref>). Familial clustering of ASD and related subclinical traits has been described, and with sibling recurrence risk estimates ranging from 8.1 to 18.7 (<xref ref-type="bibr" rid="bib19">Gronborg et al., 2013</xref>, <xref ref-type="bibr" rid="bib36">Ozonoff et al., 2011</xref>, <xref ref-type="bibr" rid="bib40">Risch et al., 2014</xref>), a significant amount of familial liability is attributed to genetic factors (<xref ref-type="bibr" rid="bib11">Colvert et al., 2015</xref>). Genomic microarray and sequencing studies have identified that ∼10% of individuals have an identifiable genetic condition, and there are over 100 genetic disorders that can exhibit features of ASD, e.g., Fragile X and Rett syndromes (<xref ref-type="bibr" rid="bib7">Betancur, 2011</xref>). Dozens of additional penetrant susceptibility genes have also been implicated in ASD (<xref ref-type="bibr" rid="bib13">De Rubeis et al., 2014</xref>, <xref ref-type="bibr" rid="bib18">Gilman et al., 2011</xref>, <xref ref-type="bibr" rid="bib37">Pinto et al., 2014</xref>, <xref ref-type="bibr" rid="bib43">Tammimies et al., 2015</xref>, <xref ref-type="bibr" rid="bib50">Yuen et al., 2017</xref>), some being used in clinical testing (<xref ref-type="bibr" rid="bib10">Carter and Scherer, 2013</xref>, <xref ref-type="bibr" rid="bib16">Fernandez and Scherer, 2017</xref>). Genetically identified ASD-risk genes are enriched in broader functional groups consisting of synapse function, RNA processing, and transcriptional regulation (<xref ref-type="bibr" rid="bib8">Bourgeron, 2015</xref>, <xref ref-type="bibr" rid="bib13">De Rubeis et al., 2014</xref>, <xref ref-type="bibr" rid="bib17">Geschwind and State, 2015</xref>, <xref ref-type="bibr" rid="bib37">Pinto et al., 2014</xref>, <xref ref-type="bibr" rid="bib51">Yuen et al., 2016</xref>, <xref ref-type="bibr" rid="bib50">Yuen et al., 2017</xref>). Importantly, so far, each risk gene or copy number variation (CNV) implicated in ASD accounts for &lt;1% of cases, suggesting significant genetic heterogeneity (<xref ref-type="bibr" rid="bib50">Yuen et al., 2017</xref>). Even within families, siblings can carry different penetrant mutations (<xref ref-type="bibr" rid="bib17">Geschwind and State, 2015</xref>, <xref ref-type="bibr" rid="bib28">Leppa et al., 2016</xref>, <xref ref-type="bibr" rid="bib52">Yuen et al., 2015</xref>). Common genetic variants may also contribute to ASD risk (<xref ref-type="bibr" rid="bib45">Weiner et al., 2017</xref>).</p>
<p id="p0030">Until recently, postmortem brains were the only source of human cortical neurons to study directly the mechanistic and functional roles of ASD candidate genes <italic>in vitro</italic> (<xref ref-type="bibr" rid="bib44">Varghese et al., 2017</xref>, <xref ref-type="bibr" rid="bib47">Wintle et al., 2011</xref>). However, the still small numbers of biobanked brains, and the heterogeneous cellular content of the organ itself, as well as issues of cell viability and health are difficult to properly control in ASD (<xref ref-type="bibr" rid="bib2">Anagnostou et al., 2014</xref>, <xref ref-type="bibr" rid="bib12">de la Torre-Ubieta et al., 2016</xref>). The terminal differentiation status of mature neurons also precludes any potential <italic>in vitro</italic> studies in particular for early-onset conditions like ASD. Alternatively, somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs) that can grow indefinitely <italic>in vitro</italic> (<xref ref-type="bibr" rid="bib42">Takahashi et al., 2007</xref>). Such patient-specific iPSCs provide a newfound ability to study developmental processes, and functional characteristics, directly. Importantly, differentiation of human iPSCs into forebrain glutamatergic neurons may lead to model systems that recapitulate early molecular events in the trajectory of ASD development (<xref ref-type="bibr" rid="bib20">Habela et al., 2016</xref>, <xref ref-type="bibr" rid="bib34">Moretto et al., 2018</xref>). Directed induction into excitatory neurons can be achieved with high efficiency using transient ectopic expression of the transcription factor NGN2 (<xref ref-type="bibr" rid="bib53">Zhang et al., 2013</xref>).</p>
<p id="p0035">We devised a precise clustered regularly interspaced short palindromic repeats (CRISPR)-based strategy to efficiently generate complete knockout (KO) of any ASD-relevant gene, with all mutations made in the same “isogenic” (identical genetic background) human control iPSC line. We used the CRISPR/Cas9-mediated double-strand break mechanism coupled with error-free single-stranded template repair (SSTR) pathways (<xref ref-type="bibr" rid="bib33">Miyaoka et al., 2014</xref>) to introduce an all-reading-frame premature termination codon (named “StopTag”; <xref ref-type="fig" rid="fig1">Figure 1</xref>A) into a specific exon of a target gene, designed to prevent stable RNA/protein product from being made. We hypothesized that a collection of isogenic KO lines carrying different ASD-risk null mutations would best minimize the confounding effects of genetic background. We then explored excitatory neuron functional differences relevant to ASD for ten different successfully edited StopTag lines. Our results indicate that some ASD-risk genes display reduced synaptic activity between NGN2-derived excitatory neurons implying that ASD genes from different classes can present the same general cellular phenotype <italic>in vitro.</italic> We also highlight benefits and restrictions of studying ASD-risk genes using an isogenic human neural system.<fig id="fig1"><label>Figure 1</label><caption><p>Outline of the Experimental Procedure to Test the Phenotypical Consequences of Gene Repression in iPSC-Derived Glutamatergic Neurons</p><p>(A) Unaffected human iPSC controls (ctrl) 19-2, labeled in green, were subjected to CRISPR gene editing to introduce a premature termination codon (StopTag), into a target exon of 14 ASD target genes. Knockout (KO) iPSC populations were identified by absolute quantification of StopTag versus wild-type (wt) alleles using droplet digital PCR (ddPCR). Well A1 is an example of a cell population containing 100% wt allele (FAM signal in blue) for a given target locus, while well A2 contains 100% StopTag alleles (VIC signal in green); FAM- and VIC-associated probe sequences are presented in <xref ref-type="supplementary-material" rid="mmc1">Table S1</xref>. KO iPSCs were differentiated into glutamatergic neurons, labeled in red, by means of NGN2 transient overexpression (O/E). Neuronal phenotypes were monitored using RNA-seq, patch-clamp, and multi-electrode array recordings; F and R are ddPCR primers.</p><p>(B) Full-length integral StopTag sequence insertion was confirmed for all target genes except <italic>CHD8</italic>, in which the first 39 bp in 5′ of the StopTag sequence were deleted, and <italic>ASTN2</italic>, in which different point mutations were found (red bars); chr, chromosome; bp, base pair.</p><p>See also <xref ref-type="supplementary-material" rid="mmc1">Figures S1</xref> and <xref ref-type="supplementary-material" rid="mmc1">S2</xref> and <xref ref-type="supplementary-material" rid="mmc1">Tables S1–S3</xref>.</p></caption><graphic xlink:href="gr1"></graphic></fig></p>
</sec>
<sec id="sec2">
<title>Results</title>
<sec id="sec2.1">
<title>Selection of ASD-Risk Genes</title>
<p id="p0040">We selected 14 candidate ASD susceptibility genes from our ongoing whole-genome sequencing (WGS) project (the Autism Speaks MSSNG project), which aims to generate a list of penetrant genes for clinical diagnostics (<xref ref-type="bibr" rid="bib50">Yuen et al., 2017</xref>). The evidence and priority of each gene, at the time of its selection, for having a role in ASD is described in <xref ref-type="table" rid="tbl1">Table 1</xref>, as is its assignment within three different functional groupings, i.e., transcriptional regulation, RNA processing, and synaptic and adhesion. We also note the importance of considering the results from the models described below to human mutation data in ASD individuals, which can present in dominant, recessive, and X-linked recessive forms, and be influenced by the sex of the carrier (<xref ref-type="bibr" rid="bib10">Carter and Scherer, 2013</xref>, <xref ref-type="bibr" rid="bib17">Geschwind and State, 2015</xref>).<table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>List of 14 ASD Susceptibility Genes with Their Corresponding Functional Groupings, Transcript Levels in iPSCs, and Efficiency of Targeting</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Chr</th><th>Molecular Function</th><th>Module</th><th>ASD Gene Reference</th><th>SFARI Score</th><th>OMIM Gene</th><th>Associated Disorders</th><th>ASD Syndrome</th><th>RPKM</th><th>Targeting Efficiency</th></tr></thead><tbody><tr><td><italic>ANKRD11</italic></td><td>16</td><td>chromatin regulation</td><td>transcriptional regulation</td><td><xref ref-type="bibr" rid="bib50">Yuen et al., 2017</xref></td><td>2</td><td><ext-link ext-link-type="omim" id="intref0020" xlink:href="611192">611192</ext-link></td><td>ADHD, EPS, ID</td><td>KBG syndrome</td><td align="char">26.2</td><td>failed</td></tr><tr><td><italic>AUTS2</italic></td><td>7</td><td>chromatin binding</td><td>transcriptional regulation</td><td><xref ref-type="bibr" rid="bib50">Yuen et al., 2017</xref></td><td>3</td><td>–</td><td>ID, DD/ND</td><td>–</td><td align="char">16.6</td><td>failed</td></tr><tr><td><italic>ATRX</italic></td><td>X</td><td>chromatin binding/helicase</td><td>transcriptional regulation</td><td><xref ref-type="bibr" rid="bib9">Brett et al., 2014</xref></td><td>4</td><td><ext-link ext-link-type="omim" id="intref0025" xlink:href="300032">300032</ext-link></td><td>EP, EPS</td><td>–</td><td align="char">17.7</td><td>Hem</td></tr><tr><td><italic>CHD8</italic></td><td>14</td><td>chromatin binding/helicase</td><td>transcriptional regulation</td><td><xref ref-type="bibr" rid="bib50">Yuen et al., 2017</xref></td><td>1</td><td><ext-link ext-link-type="omim" id="intref0030" xlink:href="610528">610528</ext-link></td><td>SCZ, DD/ND ID</td><td>–</td><td align="char">27.8</td><td>Het</td></tr><tr><td><italic>AFF2</italic> (FMR2)</td><td>X</td><td>RNA binding</td><td>RNA processing</td><td><xref ref-type="bibr" rid="bib50">Yuen et al., 2017</xref></td><td>4</td><td><ext-link ext-link-type="omim" id="intref0035" xlink:href="300806">300806</ext-link></td><td>ID, ASD, EPS, EP, ADHD</td><td>fragile X syndrome</td><td align="char">1.7</td><td>Hem</td></tr><tr><td><italic>CAPRIN1</italic></td><td>11</td><td>RNA binding</td><td>RNA processing</td><td><xref ref-type="bibr" rid="bib23">Jiang et al., 2013</xref></td><td>3</td><td>–</td><td>–</td><td>–</td><td align="char">110.9</td><td>failed</td></tr><tr><td><italic>CACNA1C</italic></td><td>12</td><td>ion channel activity</td><td>synaptic and adhesion</td><td><xref ref-type="bibr" rid="bib50">Yuen et al., 2017</xref></td><td>S</td><td><ext-link ext-link-type="omim" id="intref0040" xlink:href="114205">114205</ext-link></td><td>EPS, BPD, ID</td><td>Timothy syndrome</td><td align="char">0.2</td><td>Hom</td></tr><tr><td><italic>KCNQ2</italic></td><td>20</td><td>ion channel activity</td><td>synaptic and adhesion</td><td><xref ref-type="bibr" rid="bib50">Yuen et al., 2017</xref></td><td>3</td><td><ext-link ext-link-type="omim" id="intref0045" xlink:href="602235">602235</ext-link></td><td>ADHD, DD/ND ID</td><td>–</td><td align="char">7.8</td><td>Hom</td></tr><tr><td><italic>SCN2A</italic></td><td>2</td><td>ion channel activity</td><td>synaptic and adhesion</td><td><xref ref-type="bibr" rid="bib50">Yuen et al., 2017</xref></td><td>1</td><td><ext-link ext-link-type="omim" id="intref0050" xlink:href="182390">182390</ext-link></td><td>EPS, DD/ND ADHD, ID, EP</td><td>–</td><td align="char">0.3</td><td>Hom</td></tr><tr><td><italic>ASTN2</italic></td><td>9</td><td>calcium ion binding</td><td>synaptic and adhesion</td><td><xref ref-type="bibr" rid="bib29">Lionel et al., 2014</xref></td><td>3</td><td>–</td><td>ID, EPS, DD/ND ADHD</td><td>–</td><td align="char">2.9</td><td>Hom</td></tr><tr><td><italic>DLGAP2</italic></td><td>8</td><td>synapse</td><td>synaptic and adhesion</td><td><xref ref-type="bibr" rid="bib32">Marshall et al., 2008</xref></td><td>4</td><td>–</td><td>–</td><td>–</td><td align="char">0.2</td><td>Hom</td></tr><tr><td><italic>CNTNAP2</italic></td><td>7</td><td>Cell adhesion</td><td>synaptic and adhesion</td><td><xref ref-type="bibr" rid="bib4">Bakkaloglu et al., 2008</xref></td><td>2S</td><td><ext-link ext-link-type="omim" id="intref0055" xlink:href="604569">604569</ext-link></td><td>ADHD, EP, EPS, ID</td><td>cortical dysplasia-focal epilepsy syndrome</td><td align="char">19.3</td><td>failed</td></tr><tr><td><italic>TENM1</italic> (ODZ1)</td><td>X</td><td>Cell adhesion/signal transducer</td><td>synaptic and adhesion</td><td><xref ref-type="bibr" rid="bib50">Yuen et al., 2017</xref></td><td>NA</td><td>–</td><td>–</td><td>–</td><td align="char">0.2</td><td>Hem</td></tr><tr><td><italic>ANOS1</italic> (KAL1)</td><td>X</td><td>extracellular matrix</td><td>synaptic and adhesion</td><td><xref ref-type="bibr" rid="bib23">Jiang et al., 2013</xref></td><td>NA</td><td><ext-link ext-link-type="omim" id="intref0060" xlink:href="300836">300836</ext-link></td><td>–</td><td>Kallmann syndrome</td><td align="char">35.8</td><td>Hem</td></tr></tbody></table><table-wrap-foot><fn><p>Some genes like <italic>ANOS1</italic> and <italic>TENM1</italic> were considered stronger candidates for having a role in ASD early in the study, but this changed as additional genetic studies were published. SFARI, Simons Foundation Autism Research Initiative; OMIM, Online Mendelian Inheritance in Man; ADHD, attention deficit with hyperactivity disorder; EPS, extrapyramidal symptoms; ID, intellectual disability; ASD, autism spectrum disorder; EP, epilepsy; SCZ, schizophrenia; DD/NDD, developmental delay/neurodevelopmental disorder; BPD, bipolar disorder; RPKM, reads per kilobase per million mapped reads in iPSCs; Hem, hemizygous; Het, heterozygous; Hom, homozygous; NA, not available. See also <xref ref-type="supplementary-material" rid="mmc1">Figure S2</xref> and <xref ref-type="supplementary-material" rid="mmc1">Table S2</xref>.</p></fn></table-wrap-foot></table-wrap></p>
</sec>
<sec id="sec2.2">
<title>StopTag Insertion into ASD-Risk Genes and the Isogenic Control iPSC Line</title>
<p id="p0045">We first used HEK293T cells to validate our SSTR-based strategy that involved introducing all-reading-frame premature termination codons (PTC; 3x stop; <xref ref-type="supplementary-material" rid="mmc1">Figure S1</xref>A) into the DNA corresponding to an early constitutive exon for each gene (<xref ref-type="supplementary-material" rid="mmc1">Table S1</xref>), aiming for a complete expression knockout. This insertion was delivered by a synthesized single-stranded oligodeoxynucleotide (ssODN) template (<xref ref-type="supplementary-material" rid="mmc1">Table S1</xref>). The inserted fragment, called “StopTag” (<xref ref-type="fig" rid="fig1">Figures 1</xref>A and <xref ref-type="supplementary-material" rid="mmc1">S1</xref>A), is 59 bp in length and includes a V5 epitope coding sequence. The left homology arm of ssODN was designed to insert the V5 epitope in phase with the original reading frame in order to allow the detection of truncated protein, with potential residual activity, which might have escaped non-sense mediated decay (NMD) following PTC insertion. PCR amplification confirmed the integration of the StopTag within specific target loci in <italic>CHD8</italic>, <italic>DLGAP2</italic>, and <italic>KCNQ2</italic> (<xref ref-type="supplementary-material" rid="mmc1">Figure S1</xref>B).</p>
<p id="p0050">In human iPSCs, the same StopTag insertion was used to knock out each of the 14 ASD-risk genes in a pluripotent and normal iPSC line named “Ctrl 19-2” (<xref ref-type="fig" rid="fig1">Figures 1</xref>A and <xref ref-type="fig" rid="fig2">2</xref>A–2D). This line was reprogrammed from an unaffected father of a child with ASD who carries a <italic>de novo</italic> 16p11.2 microdeletion, associated with ASD (<xref ref-type="bibr" rid="bib32">Marshall et al., 2008</xref>, <xref ref-type="bibr" rid="bib46">Weiss et al., 2008</xref>). WGS confirmed that the unaffected father did not carry the 16p11.2 microdeletion, or any other known ASD-risk variants. Enrichment of 19-2-derived KO iPSCs was based on droplet digital PCR (ddPCR) coupled with dilution culture steps (<xref ref-type="fig" rid="fig1">Figure 1</xref>A and <xref ref-type="supplementary-material" rid="mmc1">Table S2</xref>), adapted from <xref ref-type="bibr" rid="bib33">Miyaoka et al. (2014)</xref> in order to maintain the polyclonality of cellular populations during enrichment. On average, 4.2 enrichment plates per line were necessary to purify to 100% KO (<xref ref-type="supplementary-material" rid="mmc1">Table S2</xref>). In addition, we confirmed homozygous or hemizygous splicing of StopTag into all successful target loci (<xref ref-type="fig" rid="fig1">Figures 1</xref>B and <xref ref-type="supplementary-material" rid="mmc1">S2</xref>), except for <italic>KCNQ2</italic> where the second allele presented a 31-bp frameshift duplication (<xref ref-type="fig" rid="fig1">Figure 1</xref>B and <xref ref-type="table" rid="tbl1">Table 1</xref>). No overt off-target mutation was found in any KO iPSC line (<xref ref-type="supplementary-material" rid="mmc1">Table S3</xref>).<fig id="fig2"><label>Figure 2</label><caption><p>Characterization of the Control 19-2 iPSCs and Neurons</p><p>(A–D) Representative microscopic images show normal iPSC (A) pluripotency (SSEA4 and OCT4), (B) differentiation potential into the three germ layers <italic>in vitro</italic> (embryoid bodies: TUBB3, SMA, and AFP) or (C) <italic>in vivo</italic> (teratoma assays), and (D) karyotype. See also <xref ref-type="supplementary-material" rid="mmc1">Figure S4</xref>. Scale bars: 100 μm (A), 25 μm (B), and 100 μm (C).</p><p>(E) Representative traces of action potentials recorded at different current injection on the left panel, and the number of action potentials is plotted for each step of current injection on the right panel.</p><p>(F) Representative traces of sodium currents on the left panel, and currents were recorded at different potentials in voltage-clamp on the right panel; 33 control 19-2 neurons were recorded from three independent differentiation experiments at day 21–28 post-NGN2-induction (PNI).</p><p>(G) Transcript levels in RPKM of a series of iPSC, neural progenitor cell (NPC), and neuron markers in control 19-2 iPSCs (blue) and control 19-2 glutamatergic neurons (orange). Values are presented as means ± SD of eight independent experiments for iPSCs and four for neurons.</p><p>See also <xref ref-type="supplementary-material" rid="mmc1">Figure S3</xref>.</p></caption><graphic xlink:href="gr2"></graphic></fig></p>
</sec>
<sec id="sec2.3">
<title>Induction into Excitatory Neurons</title>
<p id="p0055">Since genes involved in glutamatergic neurotransmission are associated with ASD (<xref ref-type="bibr" rid="bib3">Autism Genome Project Consortium et al., 2007</xref>, <xref ref-type="bibr" rid="bib18">Gilman et al., 2011</xref>), we sought to differentiate our KO iPSC lines into excitatory neurons to explore functional differences. We used the ectopic expression of NGN2 for iPSC differentiation (<xref ref-type="fig" rid="fig1">Figure 1</xref>A) in order to achieve homogeneous populations of neurons, and a reproducible differentiation protocol for the simultaneous assessment of multiple cell lines affected by different mutations. Using this protocol, induced neurons, when co-cultured with glial cells, display repetitive action potentials, large inward currents, and spontaneous synaptic activity by 21 days in culture (<xref ref-type="bibr" rid="bib53">Zhang et al., 2013</xref>). We hypothesized that NGN2-induced mutant neurons could be used to monitor ASD state <italic>in vitro</italic>. We therefore induced NGN2 for 7 days and assessed electrophysiological properties of 19-2 control neurons using patch-clamp recordings of 21–28 days post-NGN2-induction (PNI) in the presence of cultured mouse glial cells. These 19-2 control neurons had a similar ability to fire repetitive action potentials (<xref ref-type="fig" rid="fig2">Figure 2</xref>E), and comparable input resistance, inward and outward currents (<xref ref-type="fig" rid="fig2">Figures 2</xref>F and <xref ref-type="supplementary-material" rid="mmc1">S5</xref>A). Therefore, the NGN2 induction protocol was able to generate neurons to a similar maturation as previously reported (<xref ref-type="bibr" rid="bib49">Yi et al., 2016</xref>, <xref ref-type="bibr" rid="bib53">Zhang et al., 2013</xref>), enabling us to use the system to interrogate the function of ASD genes using isogenic KO iPSCs. Here, “neuron” refers to the NGN2-induced neuron.</p>
</sec>
<sec id="sec2.4">
<title>Transcriptional Characterization of Control 19-2 iPSCs and Neurons</title>
<p id="p0060">We used RNA sequencing (RNA-seq) to verify the pluripotent state of the control 19-2 iPSCs, as well as the glutamatergic state of the control 19-2 neurons 4 weeks PNI cultured in the absence of glial cells. Transcript levels of 14 well-established pluripotency markers were high, i.e., from 33 to 783 reads per kilobase of transcript per million mapped reads (RPKM) in control iPSCs (<xref ref-type="fig" rid="fig2">Figure 2</xref>G). Expression of the same set of pluripotency markers was low in neurons, i.e., from 0 to 14 RPKM. We observed a similar pattern of expression to that published originally in NGN2-generated neurons (<xref ref-type="bibr" rid="bib53">Zhang et al., 2013</xref>). For example, we recorded higher levels of the cortical markers <italic>POU3F2</italic> and <italic>FOXG1</italic> than those of <italic>TBR1</italic> (<xref ref-type="fig" rid="fig2">Figure 2</xref>G). AMPA receptor subunits <italic>GRIA1</italic>, <italic>GRIA2</italic>, and <italic>GRIA4</italic> were highly represented at &gt;10 RPKM, compared with the NMDA receptor subunit <italic>GRIN1</italic> at 1.5 RPKM, and transcript levels for the glutamate transporter <italic>SLC17A6</italic> were high, while those of <italic>SLC17A7</italic> were much lower (<xref ref-type="fig" rid="fig2">Figure 2</xref>G). GABA receptor subunit <italic>GABRA2</italic> transcript levels were seen at higher levels compared with those of the GABA transporter <italic>SLC32A1</italic> (<xref ref-type="fig" rid="fig2">Figure 2</xref>G). We also observed high levels of the neuronal markers <italic>MAP2</italic>, <italic>TUBB3</italic>, and <italic>NCAM1</italic>, but near-zero levels of the astrocyte marker <italic>GFAP</italic> (<xref ref-type="fig" rid="fig2">Figure 2</xref>G). These data reflect a homogeneous NGN2-derived glutamatergic neuron profile, suitable for phenotyping.</p>
</sec>
<sec id="sec2.5">
<title>StopTag Leads to Complete KO of Target Genes</title>
<p id="p0065">We ensured that the StopTag sequence was properly transcribed and fused to the different target transcripts. For example, a part of some reads generated from RNA-seq did not align with exon 2 of <italic>SCN2A</italic> on the human reference genome hg19 (<xref ref-type="fig" rid="fig3">Figure 3</xref>A), corresponding exactly to the StopTag sequence, which should cause premature termination of translation. We observed a significant reduction in transcript levels of five target genes (<xref ref-type="fig" rid="fig3">Figure 3</xref>B). For instance, transcript levels of <italic>ATRX</italic> were reduced by ∼50% in both <italic>ATRX</italic><sup>−/y</sup> iPSCs and neurons compared with control cells (<xref ref-type="fig" rid="fig3">Figure 3</xref>B). This suggests that some mutant transcripts were eliminated by NMD before complete translation due to the presence of a PTC, brought by StopTag. However, we did not observe such reduction in transcript levels for the synaptic genes <italic>CACNA1C</italic>, <italic>KCNQ2</italic>, <italic>SCN2A</italic>, <italic>DLGAP2</italic>, and <italic>TENM1</italic> (<xref ref-type="fig" rid="fig3">Figure 3</xref>B and <xref ref-type="supplementary-material" rid="mmc1">Table S4</xref>), suggesting that these transcripts may escape NMD at least until the time of RNA extraction. Despite transcript levels, western blot analysis confirmed the absence of target proteins in mutant neurons. For example, the major protein form of <italic>ATRX</italic> was detected at 280 kDa in control 19-2 neurons, but was not detectable in <italic>ATRX</italic><sup>−/y</sup> (<xref ref-type="fig" rid="fig3">Figure 3</xref>C).<fig id="fig3"><label>Figure 3</label><caption><p>Complete KO of Target Gene Expression in Neurons</p><p>(A) Example of a target locus, i.e., exon 2 of <italic>SCN2A</italic>, where Spliced Transcripts Alignment to a Reference (STAR) software was used to align reads previously unmapped by TopHat. The gray part of the reads mapped to the human reference genome hg19. The colored part did not map to hg19 but aligned perfectly with the StopTag sequence, showing it is properly transcribed and fused to the target transcripts.</p><p>(B) Transcript levels in reads per kilobase per million mapped reads (RPKM; y axis) of each target gene (x axis) in their corresponding KO iPSCs (black bars) and KO neurons (red bars), as well as in control iPSCs (gray bars) and control neurons (blue bars). Values are presented as means ± SD of 2–8 independent experiments; <sup>∗</sup>FDR &lt;0.05 in neurons. See also <xref ref-type="supplementary-material" rid="mmc1">Table S4</xref>.</p><p>(C) Western blots showing the absence of the major form of ATRX (upper panel) and SCN2A (bottom panel) proteins in their corresponding KO neurons, compared with control 19-2 neurons, 4 weeks PNI; ACTB, loading control.</p><p>(D) Western blots revealing the absence of any truncated form of proteins in different KO neuron lines, using a V5 antibody. Predicted (kDa), predicted size of potentially truncated peptides based on the insertion sites of the StopTag within each target transcript relative to the start codon position; n/a, not applicable; ACTB and TUBB3, loading controls; n/a, not available.</p></caption><graphic xlink:href="gr3"></graphic></fig></p>
<p id="p0070">Notwithstanding, some StopTag transcripts escaping NMD might still be translated as truncated proteins and not recognized by antibodies. Such peptides are undesirable in a KO setup since they can present some residual activity or cause other unintended damage (<xref ref-type="bibr" rid="bib25">Kamiya et al., 2004</xref>, <xref ref-type="bibr" rid="bib31">Luo et al., 2017</xref>). In order to reveal the presence of any truncated form of proteins, we flanked a sequence coding for a V5 epitope upstream of the 3x stop within the StopTag fragment (<xref ref-type="fig" rid="fig1">Figure 1</xref>A). A perfect assemblage was confirmed by Sanger sequencing for most target genes (<xref ref-type="fig" rid="fig1">Figure 1</xref>B). No truncated forms of protein were detectable by western blot using a V5 antibody (<xref ref-type="fig" rid="fig3">Figure 3</xref>D), indicating complete absence of target proteins in the testable KO neurons.</p>
</sec>
<sec id="sec2.6">
<title>Transcriptional Characterization of KO iPSCs and Neurons</title>
<p id="p0075">RNA-seq profiling of the ten KO iPSC lines demonstrated their pluripotency and differentiation into glutamatergic neurons. Major iPSC markers, e.g., <italic>NANOG</italic> and <italic>POU5F1</italic>, were highly expressed exclusively in iPSCs (<xref ref-type="supplementary-material" rid="mmc1">Figure S3</xref>). Alternatively, specific neuronal markers, e.g., <italic>MAP2</italic> and <italic>SLC17A6</italic> (vGLUT2) were found expressed only in neurons (<xref ref-type="supplementary-material" rid="mmc1">Figure S3</xref>). Deficient <italic>GFAP</italic> expression indicated the absence of glial cells in our neuronal cultures (<xref ref-type="supplementary-material" rid="mmc1">Figure S3</xref>).</p>
</sec>
<sec id="sec2.7">
<title>RNA-Seq and Pathway Analysis</title>
<p id="p0080">Transcriptional co-profiling of several isogenic KO lines can reveal how different genes, belonging to different functional groupings, might regulate the expression of common gene sets or pathways. From the different lists of differentially expressed genes (DEGs) in KO iPSCs compared with controls (<xref ref-type="supplementary-material" rid="mmc2">Table S5</xref>), we explored common pathway enrichment shared by at least three of the ten KO lines. Several different gene ontology terms and pathways associated with “neuron projection development” presented a similar profile in different KO iPSC lines (<xref ref-type="fig" rid="fig4">Figure 4</xref>A). For example, most of the corresponding gene sets were downregulated in <italic>ATRX</italic>-, <italic>ASTN2</italic>-, and <italic>DLGAP2</italic>-, while they were upregulated in <italic>AFF2</italic>-null iPSCs (<xref ref-type="fig" rid="fig4">Figure 4</xref>A). A different profile was observed with the “anchored component of membrane” pathway, i.e., predominantly upregulated in <italic>AFF2</italic>- and <italic>SCN2A</italic>-, while downregulated in <italic>ATRX</italic>- and <italic>ASTN2</italic>-null lines (<xref ref-type="fig" rid="fig4">Figure 4</xref>A). Another group of gene sets, associated with “negative regulation of transcription” were commonly downregulated in <italic>ATRX</italic>-, and upregulated in <italic>AFF2</italic>- and <italic>SCN2A</italic>-null iPSCs (<xref ref-type="fig" rid="fig4">Figure 4</xref>A). In general, KO of <italic>CACNA1C</italic> or <italic>KCNQ2</italic> did not have significant impact on transcriptional networks in iPSCs (<xref ref-type="fig" rid="fig4">Figure 4</xref>A). This may suggest that some of our KO iPSC lines already show transcriptional networks that are prone to ASD-related changes.<fig id="fig4"><label>Figure 4</label><caption><p>Transcriptional Characterization of KO iPSCs and Neurons</p><p>(A) Enrichment map of differentially expressed genes in different mutant iPSCs compared with the isogenic control 19-2, as revealed by RNA-seq and pathway analysis. For example, the upper right piece of each pie represents the <italic>SCN2A</italic>-null iPSC line (see inset), in which different gene sets associated with “embryonic morphogenesis” are upregulated (red color), with respect to the control 19-2 line. The color intensity correlates with the Benjamini-Hochberg false discovery rate (BH-FDR) values, as depicted in the inset. Values were calculated from (n) independent experiments; n = 8 for ctrl 19-2; n = 4 for <italic>ATRX</italic><sup>−/y</sup>, <italic>KCNQ2</italic><sup>−/−</sup>, <italic>SCN2A</italic><sup>−/−,</sup> and <italic>ASTN2</italic><sup>−/−</sup>; n = 2 for <italic>AFF2</italic><sup><italic>−</italic>/y</sup>.</p><p>(B) Differentially expressed genes in different KO neurons compared with the isogenic control 19-2 as revealed by RNA-seq. Values are presented as log2 fold change. Values were calculated from (n) independent differentiation experiments; n = 5 for <italic>AFF2</italic><sup><italic>−/y</italic></sup>; n = 4 for ctrl 19-2, <italic>ATRX</italic><sup><italic>−/y</italic></sup>, <italic>KCNQ2</italic><sup>−/−</sup>, <italic>SCN2A</italic><sup>−/<italic>−</italic></sup>; n = 3 for <italic>ASTN2</italic><sup><italic>−/−</italic></sup>.</p><p>(C) RNA-seq validation of transcript levels of seven genes in three different <italic>AFF2</italic>-null neuron lines, i.e., 19-2-<italic>AFF2</italic><sup><italic>−/y</italic></sup>-1, 19-2-<italic>AFF2</italic><sup><italic>−/y</italic></sup>-2, and 50B-<italic>AFF2</italic><sup><italic>−/y</italic></sup>, compared with their respective control lines 19-2 and 50B. Values are presented as means ± SD of (n) independent differentiation experiments where n = 4 for controls 19-2 and 50B; n = 5 for 19-2-AFF2<sup>−/y</sup>-1; n = 3 for 19-2-AFF2<sup>−/y</sup>-2 and 50B-AFF2<sup>−/y</sup>; <sup>∗</sup>each KO line value has an FDR &lt;0.5 compared with its respective control line.</p><p>See also <xref ref-type="supplementary-material" rid="mmc1">Figure S4</xref> and <xref ref-type="supplementary-material" rid="mmc2">Tables S5–S7</xref>.</p></caption><graphic xlink:href="gr4"></graphic></fig></p>
<p id="p0085">We also mined RNA-seq data for common mechanisms in our iPSC-derived NGN2 neurons. Since the number of DEGs passing a false discovery rate (FDR) &lt;0.05 was substantially lower in neurons overall compared with iPSCs, we decided to lower the significance thresholds for some of the KO lines and searched for pathway enrichments, as explained in <xref ref-type="supplementary-material" rid="mmc3">Table S6</xref>. Gene ontology terms with a Benjamini-Hochberg false discovery rate (BH-FDR) &lt;0.05, and associated with “neurons” or “synapses,” were found in high numbers only in <italic>ATRX</italic><sup><italic>−/y</italic></sup> and <italic>TENM1</italic><sup><italic>−/y</italic></sup> lines (<xref ref-type="supplementary-material" rid="mmc3">Table S6</xref>). Therefore, we searched for common DEGs, instead of gene sets, found in at least two of ten mutant neuron lines. Several DEGs were shared between distinct KO neuron lines. For instance, <italic>ZNF558</italic> was downregulated in <italic>ATRX-</italic>, <italic>AFF2-</italic>, <italic>KCNQ2-</italic>, <italic>SCN2A-</italic>, <italic>ASTN2-</italic>, and <italic>DLGAP2</italic>-null neurons (<xref ref-type="fig" rid="fig4">Figure 4</xref>B). Conversely, <italic>REG1A</italic> was upregulated in <italic>ATRX</italic>-, <italic>AFF2</italic>-, and <italic>TENM1</italic>-null neurons (<xref ref-type="fig" rid="fig4">Figure 4</xref>B). Like in iPSCs, KO of <italic>CACNA1C</italic> did not have a major impact on the neuronal transcriptional network (<xref ref-type="fig" rid="fig4">Figure 4</xref>B). Interestingly, many upregulated DEGs shown in <xref ref-type="fig" rid="fig4">Figure 4</xref>B are also members of the cadherin superfamily PCDH involved in synapse configuration (<xref ref-type="bibr" rid="bib21">Hirano and Takeichi, 2012</xref>). Inversely, several downregulated DEGs belong to the C<sub>2</sub>H<sub>2</sub> zinc finger superfamily ZNF of putative transcription factors (<xref ref-type="bibr" rid="bib30">Liu et al., 2014</xref>) (<xref ref-type="fig" rid="fig4">Figure 4</xref>B).</p>
<p id="p0090">On a per line basis, we searched for enrichment in ASD-associated genes among the DEGs from each KO neuron line. For this, we used a proprietary list of 736 genes (highlighted in blue in <xref ref-type="supplementary-material" rid="mmc4">Table S7</xref>) associated with ASD (<xref ref-type="bibr" rid="bib1">Abrahams et al., 2013</xref>, <xref ref-type="bibr" rid="bib37">Pinto et al., 2014</xref>, <xref ref-type="bibr" rid="bib50">Yuen et al., 2017</xref>). The DEGs overlapping this list are highlighted in yellow for each of our KO neuron lines in <xref ref-type="supplementary-material" rid="mmc4">Table S7</xref>. The number of ASD-associated genes that are differentially expressed is clearly higher in <italic>ATRX</italic><sup><italic>−/y</italic></sup> or in <italic>TENM1</italic><sup><italic>−/y</italic></sup> neurons (n &gt; 30) compared with each of the other KO lines (n &lt; 5; <xref ref-type="supplementary-material" rid="mmc4">Table S7</xref>), in agreement with the number of “neuron”-associated terms in the pathway enrichment analysis (<xref ref-type="supplementary-material" rid="mmc3">Table S6</xref>). Interestingly, among the ASD-associated genes in yellow, some are concomitantly differentially expressed in separate KO lines, e.g., <italic>GPR139</italic> and <italic>HTR3A</italic>, in <italic>ATRX</italic><sup>−/y</sup>, <italic>KCNQ2</italic><sup>−/−</sup>, and <italic>ASTN2</italic><sup>−/−</sup> neurons (<xref ref-type="supplementary-material" rid="mmc4">Table S7</xref>). The differential expression analyses in both iPSCs and neurons suggest common pathways and DEGs that converge toward different synaptic factors potentially affecting functional activity of neurons (<xref ref-type="fig" rid="fig4">Figures 4</xref>A and 4B).</p>
</sec>
<sec id="sec2.8">
<title>RNA-Seq Validation in a Different Genetic Background</title>
<p id="p0095">We also suppressed the expression of <italic>AFF2</italic> in a different and unrelated iPSC line, namely 50B, which presented a normal pluripotency and karyotype (<xref ref-type="supplementary-material" rid="mmc1">Figure S4</xref>). In addition to this new KO line, i.e., 50B-<italic>AFF2</italic><sup><italic>−/y</italic></sup>, we generated a second KO line in the 19-2 background using the same method as the first 19-2-<italic>AFF2</italic><sup><italic>−/y</italic></sup> line. For optimal homogeneity of neuronal cultures, we used the same NGN2 induction protocol to obtain iPSC-derived glutamatergic neurons, on which we performed RNA-seq and differential expression analysis. We searched for significant DEGs in common with all these three <italic>AFF2</italic>-null lines, i.e., 19-2-<italic>AFF2</italic><sup><italic>−/y</italic></sup>-1, 19-2-<italic>AFF2</italic><sup><italic>−/y</italic></sup>-2, and 50B-<italic>AFF2</italic><sup><italic>−/y</italic></sup>, compared with their respective control lines 19-2 and 50B. At least seven DEGs met these criteria, i.e., <italic>AFF2</italic>, <italic>COMT</italic>, <italic>PPIEL</italic>, <italic>TXNRD2</italic>, <italic>ZNF558</italic>, <italic>ZNF736</italic>, and <italic>LOC728024</italic> (<xref ref-type="fig" rid="fig4">Figure 4</xref>C). These results confirm that at least these genes show transcript levels that are influenced by <italic>AFF2</italic>, and not only by the specific 19-2 genetic background. Accordingly, we found a low total number of DEGs in both genetic backgrounds (<xref ref-type="supplementary-material" rid="mmc1">Figure S4</xref>C), which is in line with the absence of evidence for a transcriptional role of <italic>AFF2</italic> in the literature.</p>
</sec>
<sec id="sec2.9">
<title>Patch-Clamp Electrophysiological Analysis of KO Neurons</title>
<p id="p0100">To determine if neuronal behavior was affected by any specific gene KO, we performed patch-clamp recordings on all isogenic KO neuron lines 21–28 days PNI, in co-culture with astrocytes to improve maturation. As shown in <xref ref-type="supplementary-material" rid="mmc1">Figure S5</xref>A, overall we did not detect consistent changes in baseline properties in neurons, indicating a similar level of maturity for all KO neurons compared with controls and that individual alterations were not specific to a particular gene. <italic>SCN2A</italic>-deficient neurons were a notable exception since they were significantly altered in all parameters (<xref ref-type="supplementary-material" rid="mmc1">Figure S5</xref>A), which is consistent with the known role of sodium currents in regulating neuronal excitability in mouse postnatal neurons (<xref ref-type="bibr" rid="bib38">Planells-Cases et al., 2000</xref>).</p>
<p id="p0105">We also measured neuronal activity using patch-clamp electrophysiology as this is perhaps more relevant to ASD. We found that overall, there was a significant reduction in neuronal activity based on the observation of significantly reduced spontaneous excitatory postsynaptic current (sEPSC) frequency in <italic>ATRX</italic>-, <italic>AFF2</italic>-, <italic>KCNQ2</italic>-, <italic>SCN2A</italic>-, and <italic>ASTN2</italic>-null neurons, without a corresponding change in amplitude (<xref ref-type="fig" rid="fig5">Figure 5</xref>A). Interestingly, <italic>CACNA1C</italic><sup>−/−</sup>, <italic>DLGAP2</italic><sup>−/−</sup>, and <italic>ANOS1</italic><sup><italic>−</italic>/y</sup> neurons also displayed non-significant reductions in sEPSC frequency (<xref ref-type="fig" rid="fig5">Figure 5</xref>A). Conversely, <italic>TENM1</italic><sup><italic>−</italic>/y</sup> tended toward a non-significant higher frequency of sEPSC compared with the isogenic control neurons (<xref ref-type="fig" rid="fig5">Figure 5</xref>A). Together, these data indicate that ASD-risk genes from different classifications can produce a similar electrophysiological phenotype.<fig id="fig5"><label>Figure 5</label><caption><p>Electrophysiological Phenotyping of KO iPSC-Derived Neurons</p><p>(A) Representative traces of excitatory postsynaptic current (EPSC; top panel); spontaneous EPSC frequency (lower left panel) and amplitude (lower right panel) were recorded from different KO neurons; total number of recorded neurons is indicated on the graphs; values are presented as means ± SEM of three independent differentiation experiments for all, except two for <italic>AFF2</italic> and <italic>KCNQ2</italic>, recorded at day 21–28 PNI.</p><p>(B) Representative raster plots over a 5-min recording of multi-electrode array experiments (top panels); mean firing rate (lower left panel), burst frequency (lower middle panel), and network burst frequency (lower right panel) were recorded for the five significant genes from the sEPSC frequency graph in (A). Each spike is represented with a short black line. A burst was considered as a group of at least five spikes, each separated by an inter-spike interval (ISI) of no more than 100 ms. A network burst (pink lines) was identified as a minimum of ten spikes with a maximum ISI of 100 ms, occurring on at least 25% of electrodes per well. From 21 to 55 different wells were recorded per line, with usually 6–8 wells per line per experiment. Values are presented as means ± SEM from (n) independent differentiation experiments, where n = 8 for ctrl 19-2; n = 6 for <italic>ATRX</italic><sup>−/y</sup>; n = 5 for <italic>SCN2A</italic><sup>−/−</sup>; n = 4 for <italic>AFF2</italic><sup><italic>−</italic>/y</sup>, <italic>ASTN2</italic><sup>−/−</sup>, and <italic>KCNQ2</italic><sup>−/−</sup>; recorded at week 8 PNI; <sup>∗</sup>p &lt; 0.05 from one-way ANOVA (Dunnett multiple comparison test). n/d, not detected.</p><p>See also <xref ref-type="supplementary-material" rid="mmc1">Figure S5</xref>.</p></caption><graphic xlink:href="gr5"></graphic></fig></p>
</sec>
<sec id="sec2.10">
<title>Multi-electrode Array Analysis of KO Neurons</title>
<p id="p0110">The increased density of neuronal processes &gt;28 days PNI prevented consistent clean patch-clamp recordings for longer time periods. Nonetheless, a multi-electrode array (MEA) device allows for the ability to monitor the excitability of a population of neurons in an unbiased manner by incorporating the activity of all of individual neurons in a whole well, and for long time periods in the same culture plate. We monitored the spontaneous neuronal network activity 4–8 weeks PNI using MEAs in 48-well format, in co-culture with astrocytes to improve maturation. Field recordings were acquired to estimate the activity in each well. We focused on the five genes that significantly reduced neuronal activity in <xref ref-type="fig" rid="fig5">Figure 5</xref>A, i.e., <italic>ATRX</italic>, <italic>AFF2</italic>, <italic>KCNQ2</italic>, <italic>SCN2A</italic>, and <italic>ASTN2</italic>. We sought to determine if any of these KOs would interfere with synchronized bursting events on a neuronal population level. Since the highest level of mean firing rate (MFR) was observed 8 weeks PNI in control 19-2 neurons (<xref ref-type="supplementary-material" rid="mmc1">Figure S5</xref>B), we opted to use this time point for comparison of all KO lines. We also confirmed that most of the cultures were composed of glutamatergic neurons using different receptor inhibitors (<xref ref-type="supplementary-material" rid="mmc1">Figure S5</xref>C).</p>
<p id="p0115">The MFR and network burst frequency were significantly reduced in <italic>SCN2A</italic>-null neurons compared with control (<xref ref-type="fig" rid="fig5">Figure 5</xref>B). Moreover, the burst frequency was lower in <italic>ATRX-, AFF2-</italic>, <italic>KCNQ2-</italic>, and <italic>SCN2A-</italic>null neurons (<xref ref-type="fig" rid="fig5">Figure 5</xref>B), suggesting that loss of function of these genes affects extracellular spontaneous network activity in glutamatergic neurons and reduces neuronal activity on a population level over a longer period of time. The absence of <italic>AFF2</italic> in a different genetic background, i.e., 50B-<italic>AFF2</italic><sup><italic>−</italic>/y</sup>, also led to electrophysiological deficits (<xref ref-type="supplementary-material" rid="mmc1">Figure S5</xref>D), confirming its role in neuronal activity. Importantly, these data are overall consistent on a per gene level compared with the sEPSC data obtained from individual neurons in <xref ref-type="fig" rid="fig5">Figure 5</xref>A, except <italic>ASTN2</italic>, and suggest that ASD-risk genes converge to disrupt excitatory neuronal activity.</p>
</sec>
</sec>
<sec id="sec3">
<title>Discussion</title>
<p id="p0120">We developed a new CRISPR-based strategy, named StopTag insertion, to completely and specifically knock out the expression of ASD-relevant genes. This approach allows the systematic generation of multiple isogenic KO lines and pairs well with the highly consistent NGN2 induction to study excitatory neurons. This combination is suitable for deep phenotyping of several isogenic human glutamatergic neuron cultures, which were shown to be relevant to ASD in several studies (<xref ref-type="bibr" rid="bib20">Habela et al., 2016</xref>, <xref ref-type="bibr" rid="bib34">Moretto et al., 2018</xref>). The approach revealed that a common phenotype between some “functionally” diverse ASD-risk genes is reduced synaptic activity. We demonstrated that electrophysiological properties of <italic>ATRX</italic>-, <italic>AFF2</italic>-, <italic>KCNQ2</italic>-, <italic>SCN2A</italic>-, and <italic>ASTN2</italic>-mutant neurons were severely compromised using two complementary electrophysiology approaches, i.e., patch-clamp and MEA, which allowed for more convincing conclusions when combined together. We also showed that ASD genes from different classes display disruption of common signaling networks that are associated with neuron projection and synapse assembly. These results indicate that aberrant functional connectivity is a frequent phenotype in human neurons with ASD candidate gene null mutations.</p>
<p id="p0125">We obtained a high rate of biallelic editing, i.e., four of the six successful autosomal genes <italic>CHD8</italic>, <italic>CACNA1C</italic>, <italic>KCNQ2</italic>, <italic>SCN2A</italic>, <italic>ASTN2</italic>, and <italic>DLGAP2</italic>. This is possibly due to the use of plasmids to express Cas9 and gRNAs, which are expected to be stable for a few days following nucleofection. We reasoned that the impact of a full KO on transcriptional networks might be more significantly detected compared with heterozygous cells, especially for ASD-relevant genes that act under a dominant model, and/or other genes exquisitely sensitive to dosage alterations. It will be worthwhile to attempt to make heterozygous mutants when possible, using different vectors such as the RNP complex, to compare the heterozygous state of ASD variants. However, many of the ASD-risk genes are located on chromosome X, and since 19-2 cells are of male origin, these genes were fully inactivated after one allele was targeted. A notable exception was <italic>CHD8</italic>, which was heterozygous. Despite an attempt to target our <italic>CHD8</italic><sup><italic>+/−</italic></sup> line in a second round of CRISPR experiments, we failed to isolate any biallelic <italic>CHD8</italic>-null line. It is possible that at least one copy of <italic>CHD8</italic> is indispensable for survival, as proposed previously by other teams regarding mice (<xref ref-type="bibr" rid="bib35">Nishiyama et al., 2004</xref>) and humans (<xref ref-type="bibr" rid="bib6">Bernier et al., 2014</xref>). Since no significant results were obtained in this study with <italic>CHD8</italic><sup>+/−</sup> cells, some specific phenotypes might be more difficult to replicate with heterozygous loss-of-function mutations, possibly due to lower penetrance.</p>
<p id="p0130">The NGN2-neuron system may represent an advantage compared with classic dual-SMAD inhibition differentiation protocols for phenotyping experiments that require relatively high levels of cell homogeneity. Dual-SMAD inhibition neurons are more heterogeneous, including several different types of cells, they require a longer time to mature, and may not be ideal for higher-throughput studies where multiple genes need to be compared. We found that scalability and consistency are improved by the NGN2 induction protocol. Moreover, it allows the neuronal phenotype to be tested directly and eliminates any contribution from mutant glial cells. However, one caveat to the NGN2 approach is the lack of inhibitory neurons, which may be important to analyze particular ASD genes expressed in this population, e.g., <italic>ARID1B</italic> (<xref ref-type="bibr" rid="bib24">Jung et al., 2017</xref>). In addition, our data suggest that a disruption in the excitation/inhibition balance contributes to ASD (<xref ref-type="bibr" rid="bib22">Hussman, 2001</xref>, <xref ref-type="bibr" rid="bib41">Rubenstein and Merzenich, 2003</xref>). However, to test this directly, the effect on inhibitory neurons will have to be evaluated in the future (<xref ref-type="bibr" rid="bib48">Yang et al., 2017</xref>).</p>
<p id="p0135">Interestingly, the five genes with a common sEPSC reduced neuronal activity phenotype (<xref ref-type="fig" rid="fig5">Figure 5</xref>A) fall into different molecular function groupings, i.e., <italic>ATRX</italic> in transcriptional regulation, <italic>AFF2/FMR2</italic> in RNA processing, and <italic>KCNQ2, SCN2A, ASTN2</italic> in synaptic and adhesion (<xref ref-type="table" rid="tbl1">Table 1</xref>). And KO of three of them, i.e., <italic>ATRX</italic>, <italic>AFF2</italic>, <italic>SCN2A</italic> (from three different groupings), converge to common transcriptional networks associated with, for example, “transcription regulation,” “membrane components,” and “embryonic morphogenesis” in iPSCs (<xref ref-type="fig" rid="fig4">Figure 4</xref>A), suggesting that early developmental events may be involved in the ASD trajectory. We also found common DEGs among the five sEPSC-featured mutant neurons, e.g., <italic>PCDHA6</italic>, <italic>REG1A</italic>, and <italic>ZNF558</italic> (<xref ref-type="fig" rid="fig4">Figure 4</xref>B), that might be responsible for this common phenotype. These results suggest that RNA-seq could be used to detect specific transcriptional signatures associated with ASD. Several DEGs were also shared between neurons mutant for genes from the same group, e.g., <italic>KCNQ2</italic> and <italic>SCN2A</italic>, which are both ion channel subunits; and between neurons mutant for <italic>ATRX</italic> and <italic>AFF2</italic>, which are both X-linked genes involved in intellectual disability and binding G4-quadruplexes associated with DNA and RNA, respectively (<xref ref-type="bibr" rid="bib5">Bensaid et al., 2009</xref>, <xref ref-type="bibr" rid="bib26">Law et al., 2010</xref>) (<xref ref-type="fig" rid="fig4">Figure 4</xref>B). Although the total number of DEGs was relatively low in our KO neurons, some were validated in a different genetic background (line 50B in <xref ref-type="fig" rid="fig4">Figure 4</xref>C) and were previously associated with ASD, including <italic>COMT</italic>, which was associated with schizophrenia (<xref ref-type="bibr" rid="bib27">Lee et al., 2005</xref>). Different reasons to account for the low number of DEGs found overall in neurons can be posited. For instance, despite relative cell homogeneity obtained with the NGN2 induction system, we believe that our neuron cultures presented higher levels of variation in cell composition compared with our iPSC cultures, and that such variation decreased the statistical power to find DEGs. Another reason may be that the impact on transcriptional networks occurs prior to terminal differentiation of NGN2 neurons, e.g., on proliferation of neural progenitor cells (NPCs) as previously shown with <italic>Chd8</italic> in mice (<xref ref-type="bibr" rid="bib15">Durak et al., 2016</xref>).</p>
<p id="p0140">In conclusion, we have designed a CRISPR gene editing strategy for complete KO of ten ASD-risk genes of varying function and shown that they can be responsible for similar transcriptional rewiring and electrophysiological phenotypes in human iPSC-derived glutamatergic neurons. Overall, given the heterogeneity involved in ASD (<xref ref-type="bibr" rid="bib52">Yuen et al., 2015</xref>, <xref ref-type="bibr" rid="bib50">Yuen et al., 2017</xref>), we believe that this type of CRISPR-isogenic KO system may be essential for stepwise controlled cellular phenotyping experiments. Whole-animal murine KO models would also be useful but the same efficiencies would not be possible. For future experiments, our isogenic KO system could also be used for the incremental creation of isogenic knockin lines where other ASD patient mutations, combinatorically, could be introduced, creating a resource for advanced functional modeling and new therapeutic testing.</p>
</sec>
<sec id="sec4">
<title>Experimental Procedures</title>
<p id="p0145">Reprogramming of iPSCs was performed under the approval of the Canadian Institutes of Health Research Stem Cell Oversight Committee, and the Research Ethics Board of The Hospital for Sick Children, Toronto. Reprogramming was performed from skin fibroblasts or blood cells using retrovirus, lentivirus, or Sendai virus to deliver the reprogramming factors, and iPSCs were maintained in mTeSR (STEMCELL Technologies); see <xref ref-type="sec" rid="app3">Supplemental Information</xref>. The type II CRISPR/Cas9 double-nicking (Cas9D10A) (<xref ref-type="bibr" rid="bib39">Ran et al., 2013</xref>) system with dual guide RNA (<xref ref-type="supplementary-material" rid="mmc1">Table S1</xref>), or ribonucleoprotein (RNP complexes) was used to insert the StopTag fragment in the presence of an ssODN template, and off-target events were searched using WGS (details in the <xref ref-type="sec" rid="app3">Supplemental Information</xref>). Isolation of edited iPSCs was based on ddPCR and enrichment steps and was adapted from <xref ref-type="bibr" rid="bib33">Miyaoka et al. (2014)</xref> (see <xref ref-type="sec" rid="app3">Supplemental Information</xref>). Induction of iPSCs into glutamatergic neurons was conducted using overexpression of NGN2 for a week as described in <xref ref-type="sec" rid="app3">Supplemental Information</xref>. For RNA-seq, RNA libraries were prepared using NEBNext Ultra RNA Library Preparation kit for Illumina, and total RNA was used for poly(A) mRNA enrichment; pathway enrichment analysis was performed using the R package goseq version 1.28.0 and R version 3.4.1 (June 30, 2017) using a custom gene-set collection including gene ontology (GO, obtained from the R package GO.db version 3.4.1) and pathways (KEGG and Reactome collections downloaded from the respective websites on October 16, 2017); see <xref ref-type="sec" rid="app3">Supplemental Information</xref> for more details. In electrophysiology, whole-cell recordings (BX51WI; Olympus) were performed at room temperature using an Axoclamp 700B amplifier (Molecular Devices) from borosilicate patch electrodes (P-97 puller; Sutter Instruments); multi-electrode array recordings were made using the Axion Maestro MEA reader (Axion Biosystems), as described in the <xref ref-type="sec" rid="app3">Supplemental Information</xref>.</p>
</sec>
<sec id="sec5">
<title>Author Contributions</title>
<p id="p0150">E.D., R.K.C.Y., K.K.S., J.E., and S.W.S. designed the research project. E.D., S.H.W., M.F., P.J.R., W.W., and A.P. contributed to cell maintenance, characterization, and differentiation. E.D. conceived the StopTag KO strategy. E.D., M.F., and K.Z. contributed to the CRISPR experiments. Z.W. performed WGS off-target analyses. D.C.R. performed western blots. R.A., G.P., B.T., E.D., G.K., and D.M. participated in RNA-seq and pathway analysis. E.D. and S.H.W. performed electrophysiological experiments. J.L.H., V.K., S.W., A.C.L., and P.P. provided technical help. E.D., S.H.W., K.K.S., J.E., and S.W.S. wrote the manuscript and supervised the project. Specific contributions of the co-corresponding authors: K.K.S. lab differentiated iPSCs to neurons and conducted patch-clamp electrophysiology experiments; J.E. lab generated iPSC and differentiated to neurons for expression analyses and multi-electrode arrays; S.W.S. lab performed the CRISPR editing, WGS, and RNA-seq experiments.</p>
</sec>
</body>
<back>
<ref-list id="cebib0010">
<title>References</title>
<ref id="bib1">
<element-citation id="sref1" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abrahams</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Arking</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Mefford</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Menashe</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Wadkins</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Banerjee-Basu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Packer</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>SFARI Gene 2.0: a community-driven knowledgebase for the autism spectrum disorders (ASDs)</article-title>
<source/>Mol. Autism
          <volume>4</volume>
<year>2013</year>
<fpage>36</fpage>
<pub-id pub-id-type="pmid">24090431</pub-id>
</element-citation>
</ref>
<ref id="bib2">
<element-citation id="sref2" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anagnostou</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zwaigenbaum</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Szatmari</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fombonne</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Woodbury-Smith</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Brian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bryson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>I.M.</given-names>
</name>
<name>
<surname>Drmic</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Autism spectrum disorder: advances in evidence-based practice</article-title>
<source/>CMAJ
          <volume>186</volume>
<year>2014</year>
<fpage>509</fpage>
<lpage>519</lpage>
<pub-id pub-id-type="pmid">24418986</pub-id>
</element-citation>
</ref>
<ref id="bib3">
<element-citation id="sref3" publication-type="journal">
<person-group person-group-type="author">
<collab>Autism Genome Project Consortium</collab>
<name>
<surname>Szatmari</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Paterson</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Zwaigenbaum</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Brian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.Q.</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Skaug</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>A.P.</given-names>
</name>
</person-group>
<article-title>Mapping autism risk loci using genetic linkage and chromosomal rearrangements</article-title>
<source/>Nat. Genet.
          <volume>39</volume>
<year>2007</year>
<fpage>319</fpage>
<lpage>328</lpage>
<pub-id pub-id-type="pmid">17322880</pub-id>
</element-citation>
</ref>
<ref id="bib4">
<element-citation id="sref4" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bakkaloglu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>O'Roak</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Louvi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Abelson</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Chawarska</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Klin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ercan-Sencicek</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Stillman</surname>
<given-names>A.A.</given-names>
</name>
</person-group>
<article-title>Molecular cytogenetic analysis and resequencing of contactin associated protein-like 2 in autism spectrum disorders</article-title>
<source/>Am. J. Hum. Genet.
          <volume>82</volume>
<year>2008</year>
<fpage>165</fpage>
<lpage>173</lpage>
<pub-id pub-id-type="pmid">18179895</pub-id>
</element-citation>
</ref>
<ref id="bib5">
<element-citation id="sref5" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bensaid</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Melko</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bechara</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Davidovic</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Berretta</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Catania</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Gecz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lalli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bardoni</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>FRAXE-associated mental retardation protein (FMR2) is an RNA-binding protein with high affinity for G-quartet RNA forming structure</article-title>
<source/>Nucleic Acids Res.
          <volume>37</volume>
<year>2009</year>
<fpage>1269</fpage>
<lpage>1279</lpage>
<pub-id pub-id-type="pmid">19136466</pub-id>
</element-citation>
</ref>
<ref id="bib6">
<element-citation id="sref6" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernier</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Golzio</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Stessman</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Coe</surname>
<given-names>B.P.</given-names>
</name>
<name>
<surname>Penn</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Witherspoon</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gerdts</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vulto-van Silfhout</surname>
<given-names>A.T.</given-names>
</name>
</person-group>
<article-title>Disruptive CHD8 mutations define a subtype of autism early in development</article-title>
<source/>Cell
          <volume>158</volume>
<year>2014</year>
<fpage>263</fpage>
<lpage>276</lpage>
<pub-id pub-id-type="pmid">24998929</pub-id>
</element-citation>
</ref>
<ref id="bib7">
<element-citation id="sref7" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Betancur</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting</article-title>
<source/>Brain Res.
          <volume>1380</volume>
<year>2011</year>
<fpage>42</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="pmid">21129364</pub-id>
</element-citation>
</ref>
<ref id="bib8">
<element-citation id="sref8" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bourgeron</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>From the genetic architecture to synaptic plasticity in autism spectrum disorder</article-title>
<source/>Nat. Rev. Neurosci.
          <volume>16</volume>
<year>2015</year>
<fpage>551</fpage>
<lpage>563</lpage>
<pub-id pub-id-type="pmid">26289574</pub-id>
</element-citation>
</ref>
<ref id="bib9">
<element-citation id="sref9" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brett</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>McPherson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zang</surname>
<given-names>Z.J.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ong</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Cham</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rozen</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Massively parallel sequencing of patients with intellectual disability, congenital anomalies and/or autism spectrum disorders with a targeted gene panel</article-title>
<source/>PLoS One
          <volume>9</volume>
<year>2014</year>
<fpage>e93409</fpage>
<pub-id pub-id-type="pmid">24690944</pub-id>
</element-citation>
</ref>
<ref id="bib10">
<element-citation id="sref10" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carter</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Scherer</surname>
<given-names>S.W.</given-names>
</name>
</person-group>
<article-title>Autism spectrum disorder in the genetics clinic: a review</article-title>
<source/>Clin. Genet.
          <volume>83</volume>
<year>2013</year>
<fpage>399</fpage>
<lpage>407</lpage>
<pub-id pub-id-type="pmid">23425232</pub-id>
</element-citation>
</ref>
<ref id="bib11">
<element-citation id="sref11" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colvert</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tick</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>McEwen</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Curran</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Woodhouse</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gillan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hallett</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lietz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Garnett</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Heritability of autism spectrum disorder in a UK population-based twin sample</article-title>
<source/>JAMA Psychiatry
          <volume>72</volume>
<year>2015</year>
<fpage>415</fpage>
<lpage>423</lpage>
<pub-id pub-id-type="pmid">25738232</pub-id>
</element-citation>
</ref>
<ref id="bib12">
<element-citation id="sref12" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de la Torre-Ubieta</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Won</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>D.H.</given-names>
</name>
</person-group>
<article-title>Advancing the understanding of autism disease mechanisms through genetics</article-title>
<source/>Nat. Med.
          <volume>22</volume>
<year>2016</year>
<fpage>345</fpage>
<lpage>361</lpage>
<pub-id pub-id-type="pmid">27050589</pub-id>
</element-citation>
</ref>
<ref id="bib13">
<element-citation id="sref13" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Rubeis</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Poultney</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Samocha</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cicek</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Kou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fromer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Synaptic, transcriptional and chromatin genes disrupted in autism</article-title>
<source/>Nature
          <volume>515</volume>
<year>2014</year>
<fpage>209</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="pmid">25363760</pub-id>
</element-citation>
</ref>
<ref id="bib14">
<element-citation id="sref14" publication-type="book">
<person-group person-group-type="author">
<name>
<surname>DSM-V</surname>
</name>
</person-group>
<chapter-title>Diagnostic and Statistical Manual of Mental Disorders</chapter-title>
<edition>Fifth Edition</edition>
<year>2013</year>
<publisher-name>American Psychiatric Association</publisher-name>
</element-citation>
</ref>
<ref id="bib15">
<element-citation id="sref15" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durak</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kaeser-Woo</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Rueda</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Martorell</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Nott</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.Y.</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>L.H.</given-names>
</name>
</person-group>
<article-title>Chd8 mediates cortical neurogenesis via transcriptional regulation of cell cycle and Wnt signaling</article-title>
<source/>Nat. Neurosci.
          <volume>19</volume>
<year>2016</year>
<fpage>1477</fpage>
<lpage>1488</lpage>
<pub-id pub-id-type="pmid">27694995</pub-id>
</element-citation>
</ref>
<ref id="bib16">
<element-citation id="sref16" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandez</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Scherer</surname>
<given-names>S.W.</given-names>
</name>
</person-group>
<article-title>Syndromic autism spectrum disorders: moving from a clinically defined to a molecularly defined approach</article-title>
<source/>Dialogues Clin. Neurosci.
          <volume>19</volume>
<year>2017</year>
<fpage>353</fpage>
<lpage>371</lpage>
<pub-id pub-id-type="pmid">29398931</pub-id>
</element-citation>
</ref>
<ref id="bib17">
<element-citation id="sref17" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geschwind</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>State</surname>
<given-names>M.W.</given-names>
</name>
</person-group>
<article-title>Gene hunting in autism spectrum disorder: on the path to precision medicine</article-title>
<source/>Lancet Neurol.
          <volume>14</volume>
<year>2015</year>
<fpage>1109</fpage>
<lpage>1120</lpage>
<pub-id pub-id-type="pmid">25891009</pub-id>
</element-citation>
</ref>
<ref id="bib18">
<element-citation id="sref18" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilman</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Iossifov</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ronemus</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wigler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vitkup</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses</article-title>
<source/>Neuron
          <volume>70</volume>
<year>2011</year>
<fpage>898</fpage>
<lpage>907</lpage>
<pub-id pub-id-type="pmid">21658583</pub-id>
</element-citation>
</ref>
<ref id="bib19">
<element-citation id="sref19" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gronborg</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Schendel</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Parner</surname>
<given-names>E.T.</given-names>
</name>
</person-group>
<article-title>Recurrence of autism spectrum disorders in full- and half-siblings and trends over time: a population-based cohort study</article-title>
<source/>JAMA Pediatr.
          <volume>167</volume>
<year>2013</year>
<fpage>947</fpage>
<lpage>953</lpage>
<pub-id pub-id-type="pmid">23959427</pub-id>
</element-citation>
</ref>
<ref id="bib20">
<element-citation id="sref20" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Habela</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ming</surname>
<given-names>G.L.</given-names>
</name>
</person-group>
<article-title>Modeling synaptogenesis in schizophrenia and autism using human iPSC derived neurons</article-title>
<source/>Mol. Cell. Neurosci.
          <volume>73</volume>
<year>2016</year>
<fpage>52</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="pmid">26655799</pub-id>
</element-citation>
</ref>
<ref id="bib21">
<element-citation id="sref21" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirano</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Takeichi</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Cadherins in brain morphogenesis and wiring</article-title>
<source/>Physiol. Rev.
          <volume>92</volume>
<year>2012</year>
<fpage>597</fpage>
<lpage>634</lpage>
<pub-id pub-id-type="pmid">22535893</pub-id>
</element-citation>
</ref>
<ref id="bib22">
<element-citation id="sref22" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hussman</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Suppressed GABAergic inhibition as a common factor in suspected etiologies of autism</article-title>
<source/>J. Autism Dev. Disord.
          <volume>31</volume>
<year>2001</year>
<fpage>247</fpage>
<lpage>248</lpage>
<pub-id pub-id-type="pmid">11450824</pub-id>
</element-citation>
</ref>
<ref id="bib23">
<element-citation id="sref23" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Yuen</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ju</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing</article-title>
<source/>Am. J. Hum. Genet.
          <volume>93</volume>
<year>2013</year>
<fpage>249</fpage>
<lpage>263</lpage>
<pub-id pub-id-type="pmid">23849776</pub-id>
</element-citation>
</ref>
<ref id="bib24">
<element-citation id="sref24" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Moffat</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dravid</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Gurumurthy</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>W.Y.</given-names>
</name>
</person-group>
<article-title>Arid1b haploinsufficiency disrupts cortical interneuron development and mouse behavior</article-title>
<source/>Nat. Neurosci.
          <volume>20</volume>
<year>2017</year>
<fpage>1694</fpage>
<lpage>1707</lpage>
<pub-id pub-id-type="pmid">29184203</pub-id>
</element-citation>
</ref>
<ref id="bib25">
<element-citation id="sref25" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamiya</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kaneda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sugawara</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mazaki</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Okamura</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Montal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Makita</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fukushima</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fujiwara</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>A nonsense mutation of the sodium channel gene SCN2A in a patient with intractable epilepsy and mental decline</article-title>
<source/>J. Neurosci.
          <volume>24</volume>
<year>2004</year>
<fpage>2690</fpage>
<lpage>2698</lpage>
<pub-id pub-id-type="pmid">15028761</pub-id>
</element-citation>
</ref>
<ref id="bib26">
<element-citation id="sref26" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Law</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Lower</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Voon</surname>
<given-names>H.P.</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Garrick</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Viprakasit</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mitson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>De Gobbi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marra</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner</article-title>
<source/>Cell
          <volume>143</volume>
<year>2010</year>
<fpage>367</fpage>
<lpage>378</lpage>
<pub-id pub-id-type="pmid">21029860</pub-id>
</element-citation>
</ref>
<ref id="bib27">
<element-citation id="sref27" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Joo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Association of Ala72Ser polymorphism with COMT enzyme activity and the risk of schizophrenia in Koreans</article-title>
<source/>Hum. Genet.
          <volume>116</volume>
<year>2005</year>
<fpage>319</fpage>
<lpage>328</lpage>
<pub-id pub-id-type="pmid">15645182</pub-id>
</element-citation>
</ref>
<ref id="bib28">
<element-citation id="sref28" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leppa</surname>
<given-names>V.M.</given-names>
</name>
<name>
<surname>Kravitz</surname>
<given-names>S.N.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Andrieux</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Le Caignec</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Martin-Coignard</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>DyBuncio</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Cantor</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>Rare inherited and de novo CNVs reveal complex contributions to ASD risk in multiplex families</article-title>
<source/>Am. J. Hum. Genet.
          <volume>99</volume>
<year>2016</year>
<fpage>540</fpage>
<lpage>554</lpage>
<pub-id pub-id-type="pmid">27569545</pub-id>
</element-citation>
</ref>
<ref id="bib29">
<element-citation id="sref29" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lionel</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Tammimies</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Vaags</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Ahn</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Merico</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Noor</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Runke</surname>
<given-names>C.K.</given-names>
</name>
<name>
<surname>Pillalamarri</surname>
<given-names>V.K.</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>M.T.</given-names>
</name>
</person-group>
<article-title>Disruption of the ASTN2/TRIM32 locus at 9q33.1 is a risk factor in males for autism spectrum disorders, ADHD and other neurodevelopmental phenotypes</article-title>
<source/>Hum. Mol. Genet.
          <volume>23</volume>
<year>2014</year>
<fpage>2752</fpage>
<lpage>2768</lpage>
<pub-id pub-id-type="pmid">24381304</pub-id>
</element-citation>
</ref>
<ref id="bib30">
<element-citation id="sref30" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Stubbs</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Deep vertebrate roots for mammalian zinc finger transcription factor subfamilies</article-title>
<source/>Genome Biol. Evol.
          <volume>6</volume>
<year>2014</year>
<fpage>510</fpage>
<lpage>525</lpage>
<pub-id pub-id-type="pmid">24534434</pub-id>
</element-citation>
</ref>
<ref id="bib31">
<element-citation id="sref31" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D.N.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>A dominant negative FGFR1 mutation identified in a Kallmann syndrome patient</article-title>
<source/>Gene
          <volume>621</volume>
<year>2017</year>
<fpage>1</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">28411082</pub-id>
</element-citation>
</ref>
<ref id="bib32">
<element-citation id="sref32" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marshall</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Noor</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Lionel</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Feuk</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Skaug</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shago</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Moessner</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Structural variation of chromosomes in autism spectrum disorder</article-title>
<source/>Am. J. Hum. Genet.
          <volume>82</volume>
<year>2008</year>
<fpage>477</fpage>
<lpage>488</lpage>
<pub-id pub-id-type="pmid">18252227</pub-id>
</element-citation>
</ref>
<ref id="bib33">
<element-citation id="sref33" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyaoka</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Judge</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Yoo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>T.D.</given-names>
</name>
<name>
<surname>Lizarraga</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>So</surname>
<given-names>P.L.</given-names>
</name>
<name>
<surname>Conklin</surname>
<given-names>B.R.</given-names>
</name>
</person-group>
<article-title>Isolation of single-base genome-edited human iPS cells without antibiotic selection</article-title>
<source/>Nat. Methods
          <volume>11</volume>
<year>2014</year>
<fpage>291</fpage>
<lpage>293</lpage>
<pub-id pub-id-type="pmid">24509632</pub-id>
</element-citation>
</ref>
<ref id="bib34">
<element-citation id="sref34" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moretto</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Murru</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Martano</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sassone</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Passafaro</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Glutamatergic synapses in neurodevelopmental disorders</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <volume>84</volume>
<year>2018</year>
<fpage>328</fpage>
<lpage>342</lpage>
<pub-id pub-id-type="pmid">28935587</pub-id>
</element-citation>
</ref>
<ref id="bib35">
<element-citation id="sref35" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishiyama</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tsunematsu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tsukiyama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kikuchi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>K.I.</given-names>
</name>
</person-group>
<article-title>Early embryonic death in mice lacking the beta-catenin-binding protein Duplin</article-title>
<source/>Mol. Cell. Biol.
          <volume>24</volume>
<year>2004</year>
<fpage>8386</fpage>
<lpage>8394</lpage>
<pub-id pub-id-type="pmid">15367660</pub-id>
</element-citation>
</ref>
<ref id="bib36">
<element-citation id="sref36" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozonoff</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Messinger</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yirmiya</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zwaigenbaum</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bryson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Carver</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Constantino</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Dobkins</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Recurrence risk for autism spectrum disorders: a Baby Siblings Research Consortium study</article-title>
<source/>Pediatrics
          <volume>128</volume>
<year>2011</year>
<fpage>e488</fpage>
<lpage>e495</lpage>
<pub-id pub-id-type="pmid">21844053</pub-id>
</element-citation>
</ref>
<ref id="bib37">
<element-citation id="sref37" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Delaby</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Merico</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Barbosa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Merikangas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Klei</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Thiruvahindrapuram</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ziman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Convergence of genes and cellular pathways dysregulated in autism spectrum disorders</article-title>
<source/>Am. J. Hum. Genet.
          <volume>94</volume>
<year>2014</year>
<fpage>677</fpage>
<lpage>694</lpage>
<pub-id pub-id-type="pmid">24768552</pub-id>
</element-citation>
</ref>
<ref id="bib38">
<element-citation id="sref38" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Planells-Cases</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Caprini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rockenstein</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>R.R.</given-names>
</name>
<name>
<surname>Murre</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Masliah</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Montal</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Neuronal death and perinatal lethality in voltage-gated sodium channel alpha(II)-deficient mice</article-title>
<source/>Biophys. J.
          <volume>78</volume>
<year>2000</year>
<fpage>2878</fpage>
<lpage>2891</lpage>
<pub-id pub-id-type="pmid">10827969</pub-id>
</element-citation>
</ref>
<ref id="bib39">
<element-citation id="sref39" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ran</surname>
<given-names>F.A.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C.Y.</given-names>
</name>
<name>
<surname>Gootenberg</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Konermann</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Trevino</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Matoba</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity</article-title>
<source/>Cell
          <volume>154</volume>
<year>2013</year>
<fpage>1380</fpage>
<lpage>1389</lpage>
<pub-id pub-id-type="pmid">23992846</pub-id>
</element-citation>
</ref>
<ref id="bib40">
<element-citation id="sref40" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Risch</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Croen</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Grether</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Windham</surname>
<given-names>G.C.</given-names>
</name>
</person-group>
<article-title>Familial recurrence of autism spectrum disorder: evaluating genetic and environmental contributions</article-title>
<source/>Am. J. Psychiatry
          <volume>171</volume>
<year>2014</year>
<fpage>1206</fpage>
<lpage>1213</lpage>
<pub-id pub-id-type="pmid">24969362</pub-id>
</element-citation>
</ref>
<ref id="bib41">
<element-citation id="sref41" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubenstein</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Merzenich</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>Model of autism: increased ratio of excitation/inhibition in key neural systems</article-title>
<source/>Genes Brain Behav.
          <volume>2</volume>
<year>2003</year>
<fpage>255</fpage>
<lpage>267</lpage>
<pub-id pub-id-type="pmid">14606691</pub-id>
</element-citation>
</ref>
<ref id="bib42">
<element-citation id="sref42" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tanabe</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ohnuki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Narita</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ichisaka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tomoda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamanaka</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Induction of pluripotent stem cells from adult human fibroblasts by defined factors</article-title>
<source/>Cell
          <volume>131</volume>
<year>2007</year>
<fpage>861</fpage>
<lpage>872</lpage>
<pub-id pub-id-type="pmid">18035408</pub-id>
</element-citation>
</ref>
<ref id="bib43">
<element-citation id="sref43" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tammimies</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Thiruvahindrapuram</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lionel</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Yuen</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Uddin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Weksberg</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Molecular diagnostic yield of chromosomal microarray analysis and whole-exome sequencing in children with autism spectrum disorder</article-title>
<source/>JAMA
          <volume>314</volume>
<year>2015</year>
<fpage>895</fpage>
<lpage>903</lpage>
<pub-id pub-id-type="pmid">26325558</pub-id>
</element-citation>
</ref>
<ref id="bib44">
<element-citation id="sref44" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varghese</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Keshav</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Jacot-Descombes</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Warda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wicinski</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Dickstein</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Harony-Nicolas</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>De Rubeis</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Drapeau</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Buxbaum</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>Autism spectrum disorder: neuropathology and animal models</article-title>
<source/>Acta Neuropathol.
          <volume>134</volume>
<year>2017</year>
<fpage>537</fpage>
<lpage>566</lpage>
<pub-id pub-id-type="pmid">28584888</pub-id>
</element-citation>
</ref>
<ref id="bib45">
<element-citation id="sref45" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiner</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Wigdor</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Ripke</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Kosmicki</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Grove</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Samocha</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>J.I.</given-names>
</name>
<name>
<surname>Okbay</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bybjerg-Grauholm</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Polygenic transmission disequilibrium confirms that common and rare variation act additively to create risk for autism spectrum disorders</article-title>
<source/>Nat. Genet.
          <volume>49</volume>
<year>2017</year>
<fpage>978</fpage>
<lpage>985</lpage>
<pub-id pub-id-type="pmid">28504703</pub-id>
</element-citation>
</ref>
<ref id="bib46">
<element-citation id="sref46" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiss</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Korn</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Arking</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>D.T.</given-names>
</name>
<name>
<surname>Fossdal</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Saemundsen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Stefansson</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Association between microdeletion and microduplication at 16p11.2 and autism</article-title>
<source/>N. Engl. J. Med.
          <volume>358</volume>
<year>2008</year>
<fpage>667</fpage>
<lpage>675</lpage>
<pub-id pub-id-type="pmid">18184952</pub-id>
</element-citation>
</ref>
<ref id="bib47">
<element-citation id="sref47" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wintle</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Lionel</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ginsberg</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Thiruvahindrapduram</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Pickett</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>E.H.</given-names>
</name>
</person-group>
<article-title>A genotype resource for postmortem brain samples from the Autism Tissue Program</article-title>
<source/>Autism Res.
          <volume>4</volume>
<year>2011</year>
<fpage>89</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="pmid">21254448</pub-id>
</element-citation>
</ref>
<ref id="bib48">
<element-citation id="sref48" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chanda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Marro</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Janas</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Haag</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ang</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Flores</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Mall</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Generation of pure GABAergic neurons by transcription factor programming</article-title>
<source/>Nat. Methods
          <volume>14</volume>
<year>2017</year>
<fpage>621</fpage>
<lpage>628</lpage>
<pub-id pub-id-type="pmid">28504679</pub-id>
</element-citation>
</ref>
<ref id="bib49">
<element-citation id="sref49" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Danko</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Botelho</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Patzke</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pak</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wernig</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sudhof</surname>
<given-names>T.C.</given-names>
</name>
</person-group>
<article-title>Autism-associated SHANK3 haploinsufficiency causes Ih channelopathy in human neurons</article-title>
<source/>Science
          <volume>352</volume>
<year>2016</year>
<fpage>aaf2669</fpage>
<pub-id pub-id-type="pmid">26966193</pub-id>
</element-citation>
</ref>
<ref id="bib50">
<element-citation id="sref50" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuen</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Merico</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bookman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Howe</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Thiruvahindrapuram</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>R.V.</given-names>
</name>
<name>
<surname>Whitney</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Deflaux</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bingham</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder</article-title>
<source/>Nat. Neurosci.
          <volume>20</volume>
<year>2017</year>
<fpage>602</fpage>
<lpage>611</lpage>
<pub-id pub-id-type="pmid">28263302</pub-id>
</element-citation>
</ref>
<ref id="bib51">
<element-citation id="sref51" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuen</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Merico</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Pellecchia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Alipanahi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Thiruvahindrapuram</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Genome-wide characteristics of de novo mutations in autism</article-title>
<source/>NPJ Genom. Med.
          <volume>1</volume>
<year>2016</year>
<fpage>160271</fpage>
<lpage>1602710</lpage>
<pub-id pub-id-type="pmid">27525107</pub-id>
</element-citation>
</ref>
<ref id="bib52">
<element-citation id="sref52" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuen</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Thiruvahindrapuram</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Merico</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tammimies</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hoang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chrysler</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nalpathamkalam</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pellecchia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Whole-genome sequencing of quartet families with autism spectrum disorder</article-title>
<source/>Nat. Med.
          <volume>21</volume>
<year>2015</year>
<fpage>185</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="pmid">25621899</pub-id>
</element-citation>
</ref>
<ref id="bib53">
<element-citation id="sref53" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Pak</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ahlenius</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chanda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Marro</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Patzke</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Acuna</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Covy</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Rapid single-step induction of functional neurons from human pluripotent stem cells</article-title>
<source/>Neuron
          <volume>78</volume>
<year>2013</year>
<fpage>785</fpage>
<lpage>798</lpage>
<pub-id pub-id-type="pmid">23764284</pub-id>
</element-citation>
</ref>
</ref-list>
<sec id="app1">
<title>Accession Numbers</title>
<p id="p0160">The accession number for the RNA-seq and WGS data reported in this paper is GEO: <ext-link ext-link-type="uri" id="intref0010" xlink:href="ncbi-geo:GSE107878">GSE107878</ext-link>. Specific iPSC lines are available upon request.</p>
</sec>
<sec id="app3" sec-type="supplementary-material">
<title>Supplemental Information</title>
<p id="p0170">
<supplementary-material content-type="local-data" id="mmc1">
<caption>
<title>Document S1. Supplemental Experimental Procedures, Figures S1–S5, and Tables S1–S4</title>
</caption>
<media xlink:href="mmc1.pdf"></media>
</supplementary-material>
<supplementary-material content-type="local-data" id="mmc2">
<caption>
<title>Table S5. Lists of Statistically Significant Differentially Expressed Gene Symbols in the Different Knockout iPSC Lines, Related to Figure 4</title>
</caption>
<media xlink:href="mmc2.xlsx"></media>
</supplementary-material>
<supplementary-material content-type="local-data" id="mmc3">
<caption>
<title>Table S6. Lists of Enrichment Terms in Different KO Neuronal Lines (Different Threshold Values Were Used to Select DEGs as Explained in Parentheses Besides the Line IDs), Related to Figure 4</title>
</caption>
<media xlink:href="mmc3.xlsx"></media>
</supplementary-material>
<supplementary-material content-type="local-data" id="mmc4">
<caption>
<title>Table S7. Lists of Differentially Expressed Gene Symbols in the Different Knockout Neuron Lines, According to the Significance Thresholds Described in Table S6, Related to Figure 4</title>
</caption>
<media xlink:href="mmc4.xlsx"></media>
</supplementary-material>
<supplementary-material content-type="local-data" id="mmc5">
<caption>
<title>Document S2. Article plus Supplemental Information</title>
</caption>
<media xlink:href="mmc5.pdf"></media>
</supplementary-material>
</p>
</sec>
<ack id="ack0010">
<title>Acknowledgments</title>
<p>We thank the Autism Speaks MSSNG project for genomic data and linking to research ethics board-approved consented families. We also thank Drs. Melissa Carter, Wendy Roberts, Brian Chung, and Rosanna Weksberg for obtaining skin biopsies and blood work, and the families for volunteering. We also thank Sergio Pereira, Wilson Sung, Thomas Nalpathamkalam, Darwin D'Souza, Joe Whitney, Jeff MacDonald, and Liz Li for bioinformatic support; Tara Paton, Guillermo Casallo, Barbara Kellam, Ny Hoang, and Sylvia Lamoureux for technical help; T.C. Südhof for the NGN2/rtTA lentiviral constructs. Supported by the <funding-source id="gs1">Centre for Applied Genomics</funding-source>, Canada, the <funding-source id="gs2">Canadian Institutes of Health Research</funding-source> (CIHR), Canada, the <funding-source id="gs3">Canadian Institute for Advanced Research</funding-source> (CIFAR), Canada, the <funding-source id="gs4">McLaughlin Centre</funding-source>, Canada, the <funding-source id="gs5">Canada Foundation for Innovation</funding-source> (CFI), Canada, the <funding-source id="gs6">Ontario Research Fund</funding-source> (ORF), <funding-source id="gs7">Autism Speaks</funding-source>, United States, and the <funding-source id="gs8">Hospital for Sick Children</funding-source>, Canada, Foundation. Scholarships and funding was from CIHR (FDN 143295 and XGG-125818) and ORF (GL2-01-013) to S.W.S., CFI-John R. Evans Leaders Fund (JELF)/ORF and CIHR (EPS-129129) to J.E.; CIHR (148814), <funding-source id="gs9">Ontario Brain Institute</funding-source> (OBI), Canada, <funding-source id="gs10">Natural Sciences and Engineering Research Council</funding-source> (NSERC), Canada, and the <funding-source id="gs11">Scottish Rite Charitable Foundation</funding-source> to K.K.S.; <funding-source id="gs12">NIH</funding-source> (4R33MH087908), United States, to J.E. and S.W.S.; <funding-source id="gs13">Province of Ontario Neurodevelopmental Disorders</funding-source> (POND) from OBI to J.E., S.W.S., and K.K.S.; E.D. was a recipient of the Banting Post-Doctoral Fellowship and the <funding-source id="gs14">Fonds de Recherche en Santé du Québec</funding-source> (FRQS) Post-Doctoral Fellowship; S.H.W. was supported by a Fellowship from the <funding-source id="gs15">Fragile X Research Foundation</funding-source> of Canada; D.C.R. received the <funding-source id="gs16">International Rett Syndrome Foundation</funding-source>, United States, Fellowship; P.J.R. was supported by the <funding-source id="gs17">Ontario Stem Cell Initiative</funding-source> Fellowship and the <funding-source id="gs18">Ontario Ministry of Research &amp; Innovation</funding-source> Fellowship; K.Z. was a recipient of the CIHR Canada Vanier Graduate Scholarship. S.W.S. holds the GlaxoSmithKline-CIHR chair in Genome Sciences at the University of Toronto and the Hospital for Sick Children.</p>
</ack>
<fn-group>
<fn fn-type="supplementary-material" id="app2">
<p id="p0165">Supplemental Information includes Supplemental Experimental Procedures, five figures, and seven tables and can be found with this article online at <ext-link ext-link-type="doi" id="intref0015" xlink:href="10.1016/j.stemcr.2018.10.003">https://doi.org/10.1016/j.stemcr.2018.10.003</ext-link>.</p>
</fn>
</fn-group>
</back>
</article>
</pmc-articleset>